Blue Water Acquisition III Unit. (BLUWU) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLUWU | LIMN |
|---|---|---|
| Share price | $10.42 | $2.51 |
| Market cap | — | $3.37M |
| 1-day change | 0.00% | -10.68% |
| YTD return | -1.23% | — |
| EPS (TTM) | — | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $4.67M | $-10.21M |
| 52-week high | $12.85 | $141.50 |
| 52-week low | $0.00 | $2.40 |
| Distance from 52-week high | -18.91% | -98.23% |
| Average volume | 45 | 30.88K |
| Shares outstanding | — | 1.34M |
| Employees | — | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Blue Water Acquisition III Unit.
BLUWU stock →Blue Water Acquisition Corp. III does not have significant operations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
BLUWU vs LIMN FAQ
Are Blue Water Acquisition III Unit. and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.